Onconova Therapeutics Inc. [NASDAQ: ONTX] slipped around -0.01 points on Tuesday, while shares priced at $0.26 at the close of the session, down -2.60%. The company report on November 23, 2020 that Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300.
U.S. Phase 1 trial patient enrollment to begin in the first half of 2021.
China Phase 1 trial enrollment ongoing.
Onconova Therapeutics Inc. stock is now -32.40% down from its year-to-date (YTD) trading value. ONTX Stock saw the intraday high of $0.2655 and lowest of $0.255 per share. The company’s 52-week high price is 1.56, which means current price is +36.19% above from all time high which was touched on 07/21/20.
Compared to the average trading volume of 16.82M shares, ONTX reached a trading volume of 5772362 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Onconova Therapeutics Inc. [ONTX]?
H.C. Wainwright have made an estimate for Onconova Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 01, 2018. The new note on the price target was released on January 17, 2018, representing the official price target for Onconova Therapeutics Inc. stock. Previously, the target price had yet another raise to $6, while H.C. Wainwright analysts kept a Buy rating on ONTX stock.
The Average True Range (ATR) for Onconova Therapeutics Inc. is set at 0.02, with the Price to Sales ratio for ONTX stock in the period of the last 12 months amounting to 235.97. The Price to Book ratio for the last quarter was 3.70, with the Price to Cash per share for the same quarter was set at 0.13.
How has ONTX stock performed recently?
Onconova Therapeutics Inc. [ONTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.65. With this latest performance, ONTX shares dropped by -3.40% in over the last four-week period, additionally sinking by -36.06% over the last 6 months – not to mention a rise of 84.93% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ONTX stock in for the last two-week period is set at 45.80, with the RSI for the last a single of trading hit 43.69, and the three-weeks RSI is set at 42.84 for Onconova Therapeutics Inc. [ONTX]. The present Moving Average for the last 50 days of trading for this stock 0.2770, while it was recorded at 0.2645 for the last single week of trading, and 0.4629 for the last 200 days.
Onconova Therapeutics Inc. [ONTX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Onconova Therapeutics Inc. [ONTX] shares currently have an operating margin of -994.00. Onconova Therapeutics Inc.’s Net Margin is presently recorded at -985.02.
Return on Total Capital for ONTX is now -255.87, given the latest momentum, and Return on Invested Capital for the company is -253.56. Return on Equity for this stock declined to -253.56, with Return on Assets sitting at -103.39.
Reflecting on the efficiency of the workforce at the company, Onconova Therapeutics Inc. [ONTX] managed to generate an average of -$1,131,737 per employee. Receivables Turnover for the company is 32.83 with a Total Asset Turnover recorded at a value of 0.10.Onconova Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.70 and a Current Ratio set at 2.70.
Earnings analysis for Onconova Therapeutics Inc. [ONTX]
With the latest financial reports released by the company, Onconova Therapeutics Inc. posted -0.4/share EPS, while the average EPS was predicted by analysts to be reported at -0.25/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -60.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ONTX.
Insider trade positions for Onconova Therapeutics Inc. [ONTX]
There are presently around $3 million, or 10.40% of ONTX stock, in the hands of institutional investors. The top three institutional holders of ONTX stocks are: VANGUARD GROUP INC with ownership of 6,932,899, which is approximately 13.633% of the company’s market cap and around 0.57% of the total institutional ownership; GEODE CAPITAL MANAGEMENT, LLC, holding 903,398 shares of the stock with an approximate value of $0.23 million in ONTX stocks shares; and BLACKROCK INC., currently with $0.23 million in ONTX stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Onconova Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 21 institutional holders increased their position in Onconova Therapeutics Inc. [NASDAQ:ONTX] by around 3,135,696 shares. Additionally, 12 investors decreased positions by around 1,783,641 shares, while 7 investors held positions by with 6,973,231 shares. The mentioned changes placed institutional holdings at 11,892,568 shares, according to the latest SEC report filing. ONTX stock had 8 new institutional investments in for a total of 606,437 shares, while 9 institutional investors sold positions of 1,637,401 shares during the same period.